Alkermes Expects Gradual Ramp-Up For Lybalvi Launch

Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.

Brain scan
Alkermes hopes to slowly build market for new schizophrenia/bipolar therapy

Alkermes plc is preparing to launch Lybalvi (olanzapine/samidorphan) in the fourth quarter as a new treatment option for schizophrenia and bipolar I disorder with less weight gain than traditional olanzapine, and the company is guiding investors to expect a gradual ramp up as patients cycle through the various treatment options already available, including generics.

Lybalvi (previously ALKS 3831) cleared the US Food and Drug Administration 1 June for treatment of schizophrenia in adults as well as treatment of bipolar I disorder in adults, including...

More from New Products

More from Scrip

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By 

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.